The COVID-19 pandemic has proven that research can be done more efficiently. To make these efficiencies sustainable, the sites’ perspective must be considered. Sponsors, CROs, and sites should engage early in the process to understand what is feasible–what works well and what must be fixed–to improve the way we develop new therapies and interventions that advance human health.
To discuss burning topics like these, Advarra presents Fireside Chats—a series of video conversations between research community leaders.
In this conversation, Gadi Saarony, CEO of Advarra, speaks with Deb Tatton, Senior Vice President, Global Clinical Operations at Parexel. Gadi and Deb will talk about the challenges sites face, bring awareness to these issues, and propose possible ways sponsors and CROs can work more collaboratively with sites to improve study startup and address the changing clinical trial landscape.
- Define the research challenges sites face, including pressure to quickly adapt site practices and meet expectations of the “new normal”
- Describe the enhanced role of technology (site and sponsor/CRO) in the future of clinical trials
- Outline questions sponsors and CROs can ask sites—and sites can ask sponsors and CROs—to help ensure clinical development plans are feasible and appropriate
Who Should Attend:
Clinical research professionals involved in study startup and study conduct from sponsor, CRO, institutional and site organizations.
Senior Vice President, Global Clinical Operations
Parexel is focused on supporting the development of innovative new therapies to improve patient health. We do this through a suite of services that help life science and biopharmaceutical customers across the globe transform scientific discoveries into new treatments for patients. From clinical trials to regulatory and consulting services to commercial and market access, our therapeutic, technical and functional ability is underpinned by a deep conviction in what we do.